Precision Medicines promise to provide treatments that suit specific patient populations, rather than a one-size-fits-all approach where treatments are developed with little consideration for differences between individuals. Syngene has built considerable expertise in Precision Medicines in recent years, working with both large pharma clients as well as helping new biotechs rapidly scale their programs.
Syngene’s capability lies in two key areas –– Molecularly Targeted Therapy and Immunotherapy. We have a comprehensive suite of services across NGS, cell Line engineering (CRISPR-Cas9), CAR-T proof of principle studies (autologous and allogeneic) and In-vivo oncology models (PDX/CDX/Syngeneic/Humanized). Syngene also offers extensive services across customized reagent generation, antibody development [monoclonal / bispecific/ trispecific/ antibody-drug conjugates (ADCs)], cell line development and In-vivo PK studies.
All rights reserved © 2021